Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC

Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy. On July 21, Nuvalent announced that the first patient had been dosed in ALKAZAR, which is its global Phase 3 randomized, controlled trial. The trial is evaluating neladalkib for TKI-naïve patients with advanced ALK-positive non-small cell lung cancer/NSCLC, comparing it against ALECENSA (alectinib), which is a front-line standard of care.

The ALKAZAR trial is designed to enroll ~450 TKI-naïve patients with advanced ALK-positive NSCLC. Patients will be randomized 1:1 to receive either neladalkib monotherapy or alectinib monotherapy. The primary endpoint for the trial is progression-free survival/PFS based on Blinded Independent Central Review/BICR.

Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC

A pharmacist holding a box of Exenatide, used to treat type 2 diabetes.

Neladalkib is a novel brain-penetrant ALK-selective inhibitor specifically created to overcome the limitations of currently available ALK inhibitors. It is designed to remain active in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including those with single or compound treatment-emergent ALK mutations like G1202R.

Nuvalent Inc. (NASDAQ:NUVL) is a clinical-stage biopharmaceutical company that develops therapies for patients with cancer.

While we acknowledge the potential of NUVL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NUVL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.